Monopar Therapeutics's 15min chart sees KDJ Golden Cross, Bullish Marubozu formation.

The 15-minute chart of Monopar Therapeutics recently exhibited a Golden Cross using the KDJ indicator. This occurred on September 18th at 13:30. The Bullish Marubozu formation suggests that the momentum of the stock price is shifting in a positive direction and may lead to further increases in value. The indication is that buyers are currently in control of the market, and bullish momentum is likely to persist.

On September 18, 2025, at 13:30, Monopar Therapeutics' 15-minute chart displayed a significant technical indicator: a Golden Cross using the KDJ (Kijun Sen and Tenkan Sen) indicator. This crossover, coupled with a Bullish Marubozu candlestick pattern, suggests a shift in the stock's momentum towards the upside.

The Golden Cross, a crossover of the K and D lines in the KDJ indicator, typically indicates a change from a bearish to a bullish trend. This strong technical signal aligns with a continuation of the current upward trend, signaling that the price is likely to move higher Monopar Therapeutics's 15min chart shows KDJ Golden ...^[1].

The Bullish Marubozu candlestick pattern, characterized by a long body with no shadows above or below, further confirms strong buying pressure. This pattern is often associated with a continuation of the current trend, suggesting that the price is likely to move higher Employers Holdings's 15min chart shows bullish signals ...^[2].

These signals follow a broader trend of Golden Crosses and bullish Marubozu formations observed in several other stocks, including ASGN and Cushing NextGen. Technical analysis provides valuable insights into potential stock price movements, but it is crucial for investors to consider these signals in conjunction with fundamental analysis and broader market conditions Monopar Therapeutics's 15min chart shows KDJ Golden ...^[1].

As of July 7, 2025, several notable companies have seen updates to their analyst ratings and price targets, reflecting the evolving opinions of financial experts. Positive Outlook: Alnylam Pharma (ALNY) received a "Buy" rating from Jefferies with a price target of $384.00. Chime Financial (CHYM) was initiated with an "Overweight" rating by multiple firms, including Morgan Stanley and Barclays, with targets ranging from $39.00 to $40.00. CryoPort (CYRX) was rated "Buy" by BTIG Research with a price target of $10.00. Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating. Energy Transfer (ET) was initiated with a "Buy" rating by TD Cowen with a price target of $22.00. Grab (GRAB) was rated "Buy" by Jefferies with a price target of $5.70, indicating a 20.94% upside. Home Depot (HD) was rated "Buy" by TD Cowen with a price target of $470.00. Intuit (INTU) was rated "Buy" by Morgan Stanley with a price target of $900.00. JPMorgan Chase & Co. (JPM) had a $298.00 target set by Evercore ISI with an "Outperform" rating. Kinder Morgan (KMI) was initiated with a "Buy" rating by TD Cowen. Lam Research (LRCX) had its "Buy" rating reiterated by Citigroup. MACOM Technology Solutions (MTSI) had its target raised from $136.00 to $154.00 by Truist Financial, maintaining a "Buy" rating. Monopar Therapeutics (MNPR) was initiated with an "Overweight" rating by Cantor Fitzgerald and a target of $74.00. Norwegian Cruise Line (NCLH) received a "Buy" rating from Jefferies with a price target of $29.00. Oracle (ORCL) received a "Buy" rating from UBS with a $250.00 target. Oportun Financial (OPRT) was rated "Buy" at B. Riley Financial with an $11.00 price target. Ovintiv (OVV) was rated "Buy" at Barclays Capital with a price target of $55.00. Phibro Animal Health (PAHC) was upgraded at JPMorgan Chase from Neutral to Overweight, with the price target raised from $25.00 to $35.00. Progressive (PGR) was downgraded by Morgan Stanley from Overweight to Equal Weight, with a price target of $290.00. Pulse Biosciences (PLSE) was initiated by Oppenheimer with an "Outperform" rating and a $22.00 price target. PTC (PTC) had its Overweight rating reiterated by KeyCorp Bank. Rockwell Automation (ROK) was initiated by CICC Research with a "Buy" rating and a price target of $320.00 Employers Holdings's 15min chart shows bullish signals ...^[2].

Investors should closely monitor the ongoing developments in Monopar Therapeutics and consider the broader market conditions when making investment decisions. Technical analysis, combined with fundamental analysis, can provide a more comprehensive view of potential stock price movements.